Most Read Articles
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Pearl Toh, 09 Mar 2019
The need for postoperative morphine consumption was not reduced even with the concurrent use of low-dose S-ketamine in patients who were undergoing major open gynaecological surgeries using remifentanil–propofol target-controlled infusion (TCI), a local study finds.

Superoxide dismutase: keeping cells rejuvenated

Rachel Soon
Medical Writer
12 Dec 2018

As we age, a wide range of stress factors from the environment around us can have a slow but cumulative detrimental effect on the body, even in the absence of specific disease. This manifests primarily in oxidative damage to various proteins and other components in our cells. In our December issue, MIMS Pharmacist shines a Spotlight on superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Pearl Toh, 09 Mar 2019
The need for postoperative morphine consumption was not reduced even with the concurrent use of low-dose S-ketamine in patients who were undergoing major open gynaecological surgeries using remifentanil–propofol target-controlled infusion (TCI), a local study finds.